DARA BioSciences, Inc. Announces Analytical Results in Efficacy and Dose Response of KRN5500 in Patients with Chemotherapy Induced Peripheral Neuropathy and Advanced Cancer

RALEIGH, N.C., Sept. 8, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences (Nasdaq:DARA) announced today that it presented study results from its Phase 2 multicenter, placebo controlled, double-blind, randomized dose escalation study for KRN5500 at the 13th World Congress on Pain held recently in Montreal.